These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26824277)

  • 21. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.
    Porez G; Prawitt J; Gross B; Staels B
    J Lipid Res; 2012 Sep; 53(9):1723-37. PubMed ID: 22550135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting FXR in cholestasis: hype or hope.
    Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
    Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bile acid receptors and the kidney.
    Herman-Edelstein M; Weinstein T; Levi M
    Curr Opin Nephrol Hypertens; 2018 Jan; 27(1):56-62. PubMed ID: 29045336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Progress on Bile Acid Receptor Modulators for Treatment of Metabolic Diseases.
    Xu Y
    J Med Chem; 2016 Jul; 59(14):6553-79. PubMed ID: 26878262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice.
    Li Z; Huang J; Wang F; Li W; Wu X; Zhao C; Zhao J; Wei H; Wu Z; Qian M; Sun P; He L; Jin Y; Tang J; Qiu W; Siwko S; Liu M; Luo J; Xiao J
    J Bone Miner Res; 2019 Apr; 34(4):765-776. PubMed ID: 30536462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.
    Chiang JYL; Ferrell JM
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G554-G573. PubMed ID: 31984784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
    Brønden A; Knop FK
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
    Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
    Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
    Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
    Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
    Sato H; Macchiarulo A; Thomas C; Gioiello A; Une M; Hofmann AF; Saladin R; Schoonjans K; Pellicciari R; Auwerx J
    J Med Chem; 2008 Mar; 51(6):1831-41. PubMed ID: 18307294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.
    Miyazaki-Anzai S; Masuda M; Levi M; Keenan AL; Miyazaki M
    PLoS One; 2014; 9(9):e108270. PubMed ID: 25237811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors.
    D'Amore C; Di Leva FS; Sepe V; Renga B; Del Gaudio C; D'Auria MV; Zampella A; Fiorucci S; Limongelli V
    J Med Chem; 2014 Feb; 57(3):937-54. PubMed ID: 24387325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
    Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
    Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role of the bile salt receptor FXR in atherosclerosis.
    Hageman J; Herrema H; Groen AK; Kuipers F
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bile acid signaling in renal water regulation.
    Li S; Li C; Wang W
    Am J Physiol Renal Physiol; 2019 Jul; 317(1):F73-F76. PubMed ID: 31091123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery of 12β-methyl-17-epi-18-nor-bile acids as potent and selective TGR5 agonists.
    Luxenburger A; Harris LD; Ure EM; Jiao W; Woolhouse AD; Cameron SA; Weymouth-Wilson A; Furneaux RH; Pitman JL; Hinkley SFR
    Eur J Med Chem; 2023 Mar; 250():115143. PubMed ID: 36841086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allosteric modulation of the farnesoid X receptor by a small molecule.
    Gabler M; Kramer J; Schmidt J; Pollinger J; Weber J; Kaiser A; Löhr F; Proschak E; Schubert-Zsilavecz M; Merk D
    Sci Rep; 2018 May; 8(1):6846. PubMed ID: 29717168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists.
    Schmidt J; Schierle S; Gellrich L; Kaiser A; Merk D
    Bioorg Med Chem; 2018 Aug; 26(14):4240-4253. PubMed ID: 30026040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Pharmacology of Bile Acids and Their Receptors.
    Fiorucci S; Distrutti E
    Handb Exp Pharmacol; 2019; 256():3-18. PubMed ID: 31201555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders.
    Tiwari A; Maiti P
    Drug Discov Today; 2009 May; 14(9-10):523-30. PubMed ID: 19429513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.